Literature DB >> 27298399

Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.

Xiaoxian Bill Li1, Uma Krishnamurti2, Shristi Bhattarai3, Sergey Klimov3, Michelle D Reid2, Ruth O'Regan4, Ritu Aneja3.   

Abstract

OBJECTIVES: Recent studies have shown strong correlation of pathologic complete response (pCR) to neoadjuvant chemotherapy with survival and prognosis in breast cancers.
METHODS: Clinical data from 237 breast cancer patients who received neoadjuvant chemotherapy between 2012 and 2014 were reviewed. Correlations were sought between pCR and estrogen receptor (ER), progesterone receptor (PR), and HER2 status; Nottingham and nuclear grades; tumor tubule formation; mitotic score; Ki67 index; and tumoral and stromal lymphocytic infiltration (TLI and SLI, respectively).
RESULTS: Of the 237 cases, 104 (43.9%) achieved pCR. The HER2+ and triple negative breast cancer (TNBC) subtypes had higher pCR rates compared with the luminal subtype (ER+ or PR+ and HER2-). ER and PR negativity, HER2 positivity, Nottingham grade 3, increased TLI and SLI, high mitotic count and Ki67 score correlated significantly with pCR in the overall cohort. TLI and SLI correlated significantly with pCR in the HER2+ and TNBC subtypes in multivariate analysis, whereas no biomarkers correlated with pCR in the luminal subtype.
CONCLUSIONS: In addition to the pathologic parameters and biomarkers already routinely assessed, evaluation of TLI and SLI may help to better select patients with HER2+ and TNBC for neoadjuvant chemotherapy. © American Society for Clinical Pathology, 2016. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Biomarker; Breast cancer; Neoadjuvant therapy; Pathologic complete response; TIL; Tumor infiltrating lymphocytes; pCR

Mesh：

Substances：

Year:  2016        PMID： 27298399     DOI： 10.1093/ajcp/aqw045

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN： 0002-9173            Impact factor:   2.493


  24 in total

1.  Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score.

Authors:  Jane Meisel; Chao Zhang; Cameron Neely; Pia Mendoza; Shuo You; Tatiana Han; Yuan Liu; Aysegul A Sahin; Ruth O'Regan; Xiaoxian Li
Journal:  Clin Breast Cancer       Date:  2017-12-14       Impact factor: 3.225

2.  Accuracy of Intraoperative Frozen Section of Sentinel Lymph Nodes After Neoadjuvant Chemotherapy for Breast Carcinoma.

Authors:  Anne Grabenstetter; Tracy-Ann Moo; Sabina Hajiyeva; Peter J Schüffler; Pallavi Khattar; Maria A Friedlander; Maura A McCormack; Monica Raiss; Emily C Zabor; Andrea Barrio; Monica Morrow; Marcia Edelweiss
Journal:  Am J Surg Pathol       Date:  2019-10       Impact factor: 6.394

3.  Evaluation of Pathologic Complete Response (pCR) to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients with Estrogen Receptor Positive and HER2 Negative and impact of predicting variables on pCR.

Authors:  Ramesh Omranipour; Roghiyeh Jalili; Adel Yazdankhahkenary; Abdolali Assarian; Mehrzad Mirzania; Bita Eslami
Journal:  Eur J Breast Health       Date:  2020-07-01

4.  Inflammatory Markers Predicting Pathological Complete Response in Cases with Breast Cancer Treated by Neoadjuvant Chemotherapy.

Authors:  Mahmut Büyükşimşek; Ali Oğul; Cem Mirili; Semra Paydaş
Journal:  Eur J Breast Health       Date:  2020-05-20

5.  Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer.

Authors:  Thi Truc Anh Nguyen; Lauren M Postlewait; Chao Zhang; Jane L Meisel; Ruth O'Regan; Sunil Badve; Kevin Kalinsky; Xiaoxian Li
Journal:  Breast Cancer Res Treat       Date:  2022-01-27       Impact factor: 4.872

6.  Deep Learning-Based Pathology Image Analysis Enhances Magee Feature Correlation With Oncotype DX Breast Recurrence Score.

Authors:  Hongxiao Li; Jigang Wang; Zaibo Li; Melad Dababneh; Fusheng Wang; Peng Zhao; Geoffrey H Smith; George Teodoro; Meijie Li; Jun Kong; Xiaoxian Li
Journal:  Front Med (Lausanne)       Date:  2022-06-14

7.  Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.

Authors:  Oriana A Petruolo; Melissa Pilewskie; Sujata Patil; Andrea V Barrio; Michelle Stempel; Hannah Y Wen; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2017-05-30       Impact factor: 5.344

8.  Internal Mammary Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer.

Authors:  Zhao Bi; Peng Chen; Jingjing Liu; Yanbing Liu; Pengfei Qiu; Qifeng Yang; Weizhen Zheng; Yongsheng Wang
Journal:  J Breast Cancer       Date:  2018-10-29       Impact factor: 3.588

9.  Diffusion-weighted MRI for predicting pathologic response to neoadjuvant chemotherapy in breast cancer: evaluation with mono-, bi-, and stretched-exponential models.

Authors:  Shiteng Suo; Yan Yin; Xiaochuan Geng; Dandan Zhang; Jia Hua; Fang Cheng; Jie Chen; Zhiguo Zhuang; Mengqiu Cao; Jianrong Xu
Journal:  J Transl Med       Date:  2021-06-02       Impact factor: 5.531

Review 10.  Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: A meta-analysis.

Authors:  Miaomiao Tao; Shu Chen; Xianquan Zhang; Qi Zhou
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.